Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Recruiting 2Active not recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 196Cisplatin 188Magnetic Resonance Spectroscopy 167Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 117Paclitaxel 112Oxaliplatin 110Biopsy 105venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 69sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔